JNJ Stock Recent News

Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.

Among patient investors, dividend investing has remained a standard financial strategy.

In the first six months of 2025, the stock market has been on a roller-coaster ride, hitting both lows and highs driven by trade tariff uncertainties and geopolitical tensions.

Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, though below JNJ's historical average. However, I believe the market has also priced in these issues already.

Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its balance sheet and boost growth. That changes everything, including how we invest, where we invest, and why. I'm not overhauling my strategy. But I'm sharpening my focus on pricing power, hard assets, and income that's built for this new reality.

Johnson & Johnson (JNJ -0.18%) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices.

JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.

The magic of dividends is that you don't need to do anything to earn them aside from holding the stocks that pay them. Someone who accumulates enough dividend stocks could live off their portfolio's passive income stream and never have to work another day in their life.

Johnson & Johnson is a stable, dividend-growth powerhouse with 62 years of increases and a 3.44% forward yield, ideal for conservative, long-term investors. Despite recent legal headwinds and flat core growth, JNJ remains undervalued, trading at a significant discount to the sector median P/E. Talc litigation overhang has depressed sentiment, but 95% of cases are resolved and market recovery suggests the worst is priced in.

The Dividend Income Accelerator Portfolio balances income, growth, and capital appreciation, now enhanced by the global diversification from Allianz and LVMH. We focus on financially healthy companies with sustainable dividends and strong competitive advantages, optimizing risk-reward through sector and geographic diversification. The portfolio's Weighted Average Dividend Yield [FWD] of 4.05% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.06% project a Yield on Cost above 11% in 15 years.